Jeffrey Pollock, M.D.
Endocrinology, Diabetes & Metabolism Physician in Plantation, Florida.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 8,078 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Jeffrey Pollock, M.D. reported a CMS MIPS final score of 92.9/100 - above the 83.5 national average - and filed 4,457 Medicare Part D claims in 2024.
- 92.9/100
- MIPS score · +9 vs avg
- 4K
- Part D claims, 2024
- 49%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Jeffrey Pollock, M.D.
Federal records show an active NPI with both Medicare prescribing volume and a measured CMS quality score — objective registry data, not patient reviews.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1407828320), first enumerated 02/03/2006.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 4,457 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
CMS quality reporting (MIPS)
Reported a CMS MIPS final score of 92.9/100 in the Quality Payment Program — a federal quality measure, not a patient review.
Source: CMS Quality Payment Program
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Industry payment transparency
$69.65 in reported industry payments (3 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- State context
State board disciplinary context
Florida statewide board action statistics are published annually — these figures describe aggregate state activity, not Jeffrey Pollock, M.D.'s individual license status. Verify directly with the state medical board.
Source: FLDOH annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1407828320 · Endocrinology, Diabetes & Metabolism Physician
NPI-10 · ENUM-LEGACY · TAX-MID · MIPS-ABOVE · RX-MID · BOOK-LIGHT · PHOTO-FINISH
- NPI-10 1407828320
- ENUM-LEGACY 2006
- TAX-MID 8K Endocrinology, Diabetes
- MIPS-ABOVE 92.9/100
- RX-MID 4,457
- BOOK-LIGHT 538 in Florida
- PHOTO-FINISH Saira Adeel · ±0.0
MIPS final-score neighbourhood
Same-specialty nationwide peers by CMS final score, not geographic proximity
- Pollock · this p…
Pollock · this provider
92.9 MIPS pts
- Benyamin Farahva…
Benyamin Farahvash
92.9 MIPS pts
- Saira Adeel · near
Saira Adeel
92.9 MIPS pts
- Sona Amin · near
Sona Amin
92.9 MIPS pts
- Srinivas Bontha …
Srinivas Bontha
92.9 MIPS pts
What this shows Nearest measured MIPS peers for this NUCC specialty (2023 performance year).
Jeffrey Pollock, M.D.'s MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
93 ≥ 66th percentile 66% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Jeffrey Pollock, M.D. sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,341 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Jeffrey Pollock, M.D. writes more Part D claims than 77% of them and scores higher on MIPS quality than 69% - placing this provider in the high-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Jeffrey Pollock, M.D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Jeffrey Pollock, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Jeffrey Pollock, M.D.?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Florida
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Florida providers
Endocrinology, Diabetes & Metabolism Physician ranks #98 among Florida's specialties (0.1% of in-state providers)
Each bar is a specialty's share of the Florida provider total, by primary NUCC taxonomy. The highlighted bar is Endocrinology, Diabetes & Metabolism Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Jeffrey Pollock, M.D.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 92.9/100
- vs 83.5 national avg · 2023 performance year
Quality benchmarks
- National MIPS avg 2023 measured reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
92.9/100 MIPS final score - 9.4 pts above the 83.5 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Endocrinology, Diabetes & Metabolism Physician. Quality dim: 100. Cost dim: 59.5.
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1407828320 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 02/03/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Jeffrey Pollock, M.D.'s current license status, disciplinary history, and board certifications with the Florida Board of Medicine in Florida before relying on this page for a clinical or care decision.
How we sourced this profile
Profile fields combine the CMS NPPES monthly snapshot (provider directory, taxonomy, and address) with calendar-year 2023 Medicare Part D and MIPS public-use files when records are present. NPI 1407828320 is the unique 10-digit identifier CMS uses to link Pollock across every Medicare, Medicaid, and HIPAA-covered transaction. Read full methodology →
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Jeffrey Pollock, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$70
Largest payer
Novo Nordisk Inc
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - Florida FLDOH 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~75K Florida medical licensees in 2023 - they are NOT specific to Jeffrey Pollock, M.D.. To verify Jeffrey Pollock, M.D.'s current license status, search the FLDOH public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
FLDOH publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Florida disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
44% brand-name claims vs 49% generic, on 4,457 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
Prescribing Breakdown
- 30-Day Fills
- 10,995.833
- Total Day Supply
- 326,951
- Brand vs Generic
- 44% brand / 49% generic
- Brand Drug Cost
- $1.5M
- Generic Drug Cost
- $45K
Patient Demographics
- Average Patient Age
- 74.1 years
- Avg HCC Risk Score
- 1.71
- Gender Split
- 61% female / 39% male
- Age Distribution
- <65: 38, 65-74: 268, 75-84: 223, 85+: 40
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Jeffrey Pollock, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2024
- Levothyroxine Sodium
Levothyroxine Sodium
505 claims
- Ozempic
Ozempic
398 claims
- Metformin Hcl
Metformin Hcl
364 claims
- Jardiance 191
Jardiance
191 claims
- Glipizide 167
Glipizide
167 claims
- Glimepiride 155
Glimepiride
155 claims
- Atorvastatin Calcium 151
Atorvastatin Calcium
151 claims
- Losartan Potassium 136
Losartan Potassium
136 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 505 |
| Ozempic Semaglutide | 398 |
| Metformin Hcl | 364 |
| Jardiance Empagliflozin | 191 |
| Glipizide | 167 |
| Glimepiride | 155 |
| Atorvastatin Calcium | 151 |
| Losartan Potassium | 136 |
| Tresiba Flextouch U-200 Insulin Degludec | 135 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 111 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How Jeffrey Pollock, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
Jeffrey Pollock, M.D.'s 4,457 claims are above the specialty average of 2,739.
Nationwide Endocrinology, Diabetes & Metabolism Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Pollock, both outside Florida so the neighborhoods are not geographic containment.
Similar MIPS final score
Nearest same-specialty clinicians by CMS MIPS final score (92.9 here).
Same NPPES enumeration year (2006)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Florida
Other clinicians with the same primary specialty enrolled in Florida, drawn from the same CMS NPPES roster as Pollock.
One of 538 Endocrinology, Diabetes & Metabolism Physician providers enrolled in Florida, 5 are shown here.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Jeffrey Pollock, M.D.'s specialty? ▼
How much does Jeffrey Pollock, M.D. prescribe under Medicare Part D? ▼
What is Jeffrey Pollock, M.D.'s Medicare quality score? ▼
Where is Jeffrey Pollock, M.D. located? ▼
What is Jeffrey Pollock, M.D.'s NPI number? ▼
Does Jeffrey Pollock, M.D. prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does Jeffrey Pollock, M.D. prescribe most often? ▼
Does Jeffrey Pollock, M.D. accept Medicare? ▼
How can I verify Jeffrey Pollock, M.D.'s credentials? ▼
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.
Published by
PlainDoctor
Independent public-data reference that compiles, verifies, and contextualizes official datasets. We do not accept compensation from entities we cover, and every dataset cites its originating public source.